CYP2D6 Genotyping and the Clinical Impact on Outcomes in Breast Cancer Tamoxifen-Treated Patients

References

• Sung H , FerlayJ , SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Comisión honoraria de lucha contra el Cáncer . Registro Nacional de Cáncer. Situación Epidemiológica Del Uruguay En Relación al Cáncer (2022). www.comisioncancer.org.uy/Ocultas/Situacion-Epidemiologica-del-Uruguay-en-relacion-al-Cancer--Mayo-2022-uc108
   Google Scholar
• Jordan V . Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell.5(3), 207–213 (2004). doi:10.1016/s1535-6108(04)00059-5
   PubMed Web of Science ®Google Scholar
• Ring A , DowsettM. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer.11, 643–658 (2004). doi:10.1677/erc.1.00776
   PubMed Web of Science ®Google Scholar
• Wu X , HawseJR , SubramaniamMet al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor a for degradation in breast cancer cells. Cancer Res.69(5), 1722–1727 (2009). doi:10.1158/0008-5472.CAN-08-3933
   PubMed Web of Science ®Google Scholar
• Coller JK , KrebsfaengerN , KleinKet al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br. J. Clin. Pharmacol.54, 157–167 (2002).
   PubMed Web of Science ®Google Scholar
• Schroth W , WinterS , MürdterTet al. Improved prediction of endoxifen metabolism by CYP2D6 genotype in breast cancer patients treated with tamoxifen. Front. Pharmacol.24(8), 582 (2017). doi:10.3389/fphar.2017.00582
   Google Scholar
• Binkhorst L , MathijssenRHJ , JagerA , van GelderT. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat. Rev.41(3), 289–299 (2015). doi:10.1016/j.ctrv.2015.01.002
   PubMed Web of Science ®Google Scholar
• Gaedigk A , CaseyST , Whirl-CarrilloM , MillerNA , KleinTE. Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation. Clin Pharmacol Ther.110(3), 542–545 (2021).
   PubMed Web of Science ®Google Scholar
• PharmGKB . Gene-specific information tables for CYP2D6. 3. www.pharmgkb.org/page/cyp2d6RefMaterials
   Google Scholar
• Caudle KE , SangkuhlK , Whirl-CarrilloMet al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group. Clin. Transl. Sci.13(1), 116–124 (2020). doi:10.1111/cts.12692
   PubMed Web of Science ®Google Scholar
• Clinical Pharmacogenetics Implementation Consortium . Final consensus CYP2D6 genotype to phenotype table – March (2019). https://cpicpgx.org/wp-content/uploads/2019/03/Final-Consensus-CYP2D6-genotype-to-phenotype-table_-final_Mar2019.pdf
   Google Scholar
• Gaedigk A , SimonSD , PearceRE et al. The CYP2D6 Activity Score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther.83(2), 234–242 (2008). doi:10.1038/sj.clp
   PubMed Web of Science ®Google Scholar
• He W , GrassmannF , ErikssonMet al. CYP2D6 genotype predicts tamoxifen discontinuation and prognosis in patients with breast cancer. J. Clin. Oncol.38, 548–557 (2019). doi:10.1200/JCO.19
   PubMed Web of Science ®Google Scholar
• Brooks JD , ComenEA , ReinerASet al. CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Res.20(1), 149 (2018). doi:10.1186/s13058-018-1083-y
   PubMedGoogle Scholar
• Rolla R , VidaliM , MeolaSet al. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen. Clin Lab.58(11–12), 1211–1218 (2012). doi:10.7754/Clin.Lab.2012.120114
   PubMed Web of Science ®Google Scholar
• Sans M , SalzanoFM , ChakrabortyR. Historical genetics in Uruguay: estimates of biological origins and their problems. 69, 161–170 (1997).
   Google Scholar
• The 1000 Genomes Project Consortium . A global reference for human genetic variation. Nature.526, 68–74 (2015). doi:10.1038/nature15393
   PubMed Web of Science ®Google Scholar
• Zhou Y , Ingelman-SundbergM , LauschkeVM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin. Pharmacol. Ther.102(4), 688–700 (2017). doi:10.1002/cpt.690
   PubMed Web of Science ®Google Scholar
• Ramírez B , Niño-OrregoMJ , CárdenasDet al. Copy number variation profiling in pharmacogenetics CYP-450 and GST genes in Colombian population. BMC Med. Genomics.12, 110 (2019). doi:10.1186/s12920-019-0556-x
   PubMed Web of Science ®Google Scholar
• Friedrich DC , GenroJP , SorticaVAet al. Distribution of CYP2D6 alleles and phenotypes in the Brazilian population. PLOS ONE.9(10), e110691 (2014). doi:10.1371/journal.pone.0110691
   PubMed Web of Science ®Google Scholar
• Gaedigk A , SangkuhlK , Whirl-CarrilloMet al. Prediction of CYP2D6 phenotype from genotype across world populations. Genet. Med.19(1), 69–76 (2017). doi:10.1038/gim.2016.80
   PubMed Web of Science ®Google Scholar
• Mulder TAM , de WithM , DelRe Met al. Clinical CYP2D6 genotyping to personalize adjuvant tamoxifen treatment in er-positive breast cancer patients: current status of a controversy. Cancers.13(4), 1–15 (2021). doi:10.3390/cancers13040771
   Web of Science ®Google Scholar
• He W , GrassmannF , ErikssonMet al. CYP2D6 genotype predicts tamoxifen discontinuation and prognosis in patients with breast cancer. J. Clin. Oncol.38, 548–557 (2020).
   PubMed Web of Science ®Google Scholar
• Rangel-Méndez JA , Rubi-CastellanosR , Ascencio-MontielIJ , Moo-PucRE. CYP2D6 does not impact on breast cancer-free survival in southeast Mexican patients under tamoxifen treatment. Pers. Med.17, 261–270 (2020).
   PubMed Web of Science ®Google Scholar